Research Article
Meta-Analysis of the Clinical Effectiveness and Safety of Ligustrazine in Cerebral Infarction
Table 1
Characteristics of the included studies.
| | Included studies | PY | EC | CD (h) | Study design | Sample size (M/F) | Ave. age (range or SD) | CM (d) | Interventions | Outcomes | IF | | TRE | CON | TRE (M/F) | CON (M/F) | TRE | CON | TRE | CON |
| | Ao [14] | 2004 | DCVD1995 | NA | NA | RCT | 60 | (46/14) | 60 | (47/13) | 36–78 (63.11 ± 8.22) | NA | 14 × 2 | LI 160–200 mg qd | Xuesaitong 400 mg qd | NDS | < 0.01 | | BRI | < 0.05 | | Clinical efficacy | < 0.05 |
| | Cao et al. [15] | 2007 | DCVD1995 | <72 | <72 | RCT | 72 | (48/24) | 64 | (42/22) | 49–75 (62.2 ± 12.7) | 48–75 (61.6 ± 13.4) | 14 | LHI 300 mg qd | RTWM | BRI | < 0.05 | | TNF-α level | < 0.05 | | Clinical efficacy | < 0.05 |
| | Che and Yang [16] | 2003 | DCVD1995 | 57.6 ± 12 | 60 ± 9.6 | RCT | 60 | (40/20) | 60 | (36/24) | 54 ± 5 | 55 ± 4 | 15 | LI 200 ml qd | WeinaoLutong injection 0.4 g + citicoline injection 0.5 g qd | Clinical efficacy | < 0.05 |
| | Gao [17] | 2015 | DCVD1995 | NA | NA | RCT | 36 | (17/19) | 36 | (21/15) | 47–76 (60.4 ± 8.6) | 48–78 (59.5 ± 7.5) | 14 | LI 10 ml qd | Compound Danshen injection 20 ml qd | Clinical efficacy | < 0.05 |
| | Guo and Yang [18] | 2009 | DCVD1995 | <72 | <72 | RCT | 60 | (38/22) | 50 | (34/16) | 48–78 (59.3 ± 10.4) | 49–76 (57.9 ± 13.1) | 14 | LHI 80 mg qd | Compound Danshen injection 20 ml qd | BRI | < 0.05 | | NDS | < 0.05 | | Clinical efficacy | < 0.05 |
| | Hou [19] | 2010 | DCVD1995 | NA | NA | RCT | 70 | (40/30) | 70 | (38/32) | | | 20 | LI 160 mg bid | Compound Danshen injection 20 ml + Troxerutin injection 0.6 g + sodium ozagrel 250 ml qd | Clinical efficacy | < 0.05 |
| | Huang [20] | 2008 | DCVD1996 | NA | NA | RCT | 56 | (31/25) | 56 | (33/23) | 63.7 | 63.9 | 14 | LI 160 mg qd | WeinaoLUtong injection 600 mg qd | Clinical efficacy | < 0.05 |
| | Li [21] | 2006 | DCVD1996 | <48 | <48 | RCT | 60 | NA | 64 | NA | 62.8 ± 2.4 | NA | 14 | LI 80 mg qd | Danshen injection 250 ml qd. + citicoline injection 1.0 g qd | NIHSS | < 0.01 | | BRI | < 0.05 | | | Clinical efficacy | < 0.05 |
| | Lu [22] | 2013 | DCVD1996 | <24 | <24 | RCT | 33 | NA | 33 | NA | 55–76 (65.2 ± 12.3) | NA | 14 | LI 80 mg qd | RTWM | BRI | < 0.05 | | Clinical efficacy | < 0.05 |
| | Ma [23] | 1998 | DCVD1996 | <25 | <20 | RCT | 48 | (33/15) | 40 | (27/13) | 49–80 (62) | 47–85 (64) | 14 | LI 200 mg qd | D-40 500 ml qd | Muscle strength recovery time | < 0.05 | | Clinical efficacy | < 0.05 |
| | Wan et al. [24] | 2003 | DCVD1996 | <120 | <168 | RCT | 52 | (29/23) | 50 | (30/20) | 52–83 (62.7) | 48–78 (63.2) | 14 | LHI 80 mg qd | Danshen injection 16 ml qd. | NDS | < 0.05 | | Clinical efficacy | < 0.05 |
| | Tang [25] | 2005 | DCVD1995 | 2–46 | 2–42 | RCT | 68 | (46/22) | 68 | (44/24) | 48–78 (68) | 53–77 (63) | 14 | LI 160 mg qd | Routine treatment of Western medicine | Clinical efficacy | < 0.01 |
| | Wang [26] | 2003 | DCVD1999 | NA | NA | RCT | 42 | NA | 42 | NA | 39–83 (62) | NA | 10 × 2 | LI 200 mg qd | WeinaoLutong injection 0.5 g qd | Clinical efficacy | < 0.05 |
| | Wu and Ding [27] | 2007 | DCVD1995 | <24 | <24 | RCT | 30 | (18/12) | 30 | (16/14) | 63.32 | 65.23 | 21 | LI 160 mg qd | Runtan injection 20 mg qd | BRI | < 0.05 | | NDS | < 0.01 | | GCS | < 0.01 | | Clinical efficacy | > 0.05 |
| | Xu [28] | 2007 | DCVD1996 | <72 | NA | RCT | 36 | (24/12) | 35 | (24/11) | 56–78 (62.7) | 53–81 (63.8) | 14 | LHI 80 mg bid | Compound Danshen injection 20 ml qd | BRI | < 0.05 | | Clinical efficacy | < 0.05 |
| | Xu [29] | 2007 | DCVD1995 | NA | NA | RCT | 30 | (19/11) | 30 | (17/13) | 56–82 (69.2) | 55–83 (68.7) | 14 | LI 100 mg qd | Danshen injection 16 ml qd | BI | < 0.05 | | Clinical efficacy | < 0.05 |
| | Xu et al. [30] | 1999 | DCVD1986 | 72–168 | NA | RCT | 94 | (58/36) | 92 | (56/36) | 41–76 (59.6) | 43–75 (58.8) | 12 | LI 600–800 mg qd | Nimodipine 4 mg i.v.qd + cerebrolysin 10 ml | Clinical efficacy | < 0.01 |
| | Xu et al. [31] | 2011 | DCVD1995 | 6–72 | NA | RCT | 42 | (24/18) | 40 | (24/16) | 56–78 (62.8 ± 2.5) | 55–81 (63.2 ± 2.7) | 14 | LHI 120 mg qd + ozagrel sodium chloride injection 100 ml qd + Citicoline 1.0 g qd + Asiprin 100 mg qd | Ozagrel sodium chloride injection 100 ml qd + citicoline 1.0 g qd + Aspirin 100 mg qd | BRI | < 0.05 | | NDS | < 0.05 | | Clinical efficacy | < 0.05 |
| | Zhou and Zhao [32] | 2009 | DCVD1995 | NA | NA | RCT | 50 | NA | 50 | NA | NA | NA | 14 | LHI 100 mg qd + CT | D-40 500 ml qd + CT | Clinical efficacy | < 0.01 |
|
|
PY: publication year; TRE: treatment; CON: control; M: male; F: female; Ave.: average; EC: eligibility criteria; CD: course of disease; CM: course of treatment; DCVD: diagnosis of cerebral vascular diseases; RCT: randomized controlled trial; d: day (s); h: hour (s); NDS: neurological deficit score; CT: conventional therapy (nimodipine + xuesaitong + cerebrolysin); LI = ligustrazine injection; LHI = ligustrazine hydrochloride injection; BRI: blood rheology index; BI: Barthel Index; GCS: Glasgow coma scale; RTWM: routine treatment of Western medicine (dilate blood vessel; reduce intracranial pressure; control blood pressure, blood glucose, and blood lipid; prevent infection; correct the disorder of water and electrolyte; maintain acid-base balance, etc.); NIHSS: national institutes of health stroke scale; TL: TNF-α level; CE: clinical efficacy; MSRT: muscle strength recovery time; NA: not available.
|
